Javascript must be enabled to continue!
The Multiple Stakeholder Approach to Real-world Evidence Generation: the Results of the Jandhyala Method in Observing Expert Consensus on Quality Indicators of Rare Disease Patient Registries (RDRs) by Stakeholder Group
View through CrossRef
Abstract
Background:Evidence is valuable to inform decision making. Understanding stakeholder needs from the evidence of key stakeholders is empirically important to those involved in its generation. Where multiple stakeholders exist, an understanding of whether their questions are homogenous or heterogenous necessitates a dedicated approach that will be of value to those invested in the outcomes of their decisions.The pharmaceutical industry engages with non-pharmaceutical industry stakeholders: Payors, Prescribers and, under carefully controlled circumstances, patients when commercialising its medicines. This original research focussed on the differences between these groups and their pharma aligned stakeholders: Regulatory Affairs, Market Access, Commercial and Medical Affairs using measures of their common quality indicators (QIs) from rare disease patient registries.QIs were solicited using the Jandhyala method for observing item awareness and consensus from list generating questioning. They were compared for homogeneity between individual stakeholder groups and the combined pharma and non-pharma stakeholder group population.Results:All stakeholder groups were unique and suggested items peculiar to their own group.One hundred and eleven discrete QIs were identified: Commercial (8/111; 7.21%), Market Access (6/111; 5.41%), Medical Affairs (4/111; 3.60%), Regulatory Affairs (6/111; 5.41%), Patients (14/111; 12.61%), Payors (6/111; 5.41%), and Prescribers (9/111; 8.11%). Each stakeholder's proportion of unique QIs to the total was not statistically significant to the group as a whole.Non-pharma stakeholders generated 29/111 (26.13%) unique QIs, while pharma stakeholders generated 24/111 (21.62%). The total unique QIs across both stakeholder groups were 53/111 (47.75%). Two QIs were unanimously suggested and agreed upon by all stakeholder groups (7/7; 100%): 'Engages with patients and gains their buy-in' and 'Includes a core data set as part of outcomes'.There was homogeneity in consensus on common QIs between Commercial – Market Access (P=0.006), Market Access – Regulators (P=0.006), Commercial – Prescribers (P=0.001), Market Access – Prescribers (P=0.033), and Commercial – Medical Affairs (P=0.020).Conclusions:There is sufficient evidence to support a multiple stakeholder approach for generating real-world evidence. There was a mismatch between pharma and non-pharma stakeholders of 47.75% indicating redundancies of QIs on each side of this divide. Patients and Payor (non-pharma) groups have been highlighted for greater alignment with pharma stakeholder groups.
Title: The Multiple Stakeholder Approach to Real-world Evidence Generation: the Results of the Jandhyala Method in Observing Expert Consensus on Quality Indicators of Rare Disease Patient Registries (RDRs) by Stakeholder Group
Description:
Abstract
Background:Evidence is valuable to inform decision making.
Understanding stakeholder needs from the evidence of key stakeholders is empirically important to those involved in its generation.
Where multiple stakeholders exist, an understanding of whether their questions are homogenous or heterogenous necessitates a dedicated approach that will be of value to those invested in the outcomes of their decisions.
The pharmaceutical industry engages with non-pharmaceutical industry stakeholders: Payors, Prescribers and, under carefully controlled circumstances, patients when commercialising its medicines.
This original research focussed on the differences between these groups and their pharma aligned stakeholders: Regulatory Affairs, Market Access, Commercial and Medical Affairs using measures of their common quality indicators (QIs) from rare disease patient registries.
QIs were solicited using the Jandhyala method for observing item awareness and consensus from list generating questioning.
They were compared for homogeneity between individual stakeholder groups and the combined pharma and non-pharma stakeholder group population.
Results:All stakeholder groups were unique and suggested items peculiar to their own group.
One hundred and eleven discrete QIs were identified: Commercial (8/111; 7.
21%), Market Access (6/111; 5.
41%), Medical Affairs (4/111; 3.
60%), Regulatory Affairs (6/111; 5.
41%), Patients (14/111; 12.
61%), Payors (6/111; 5.
41%), and Prescribers (9/111; 8.
11%).
Each stakeholder's proportion of unique QIs to the total was not statistically significant to the group as a whole.
Non-pharma stakeholders generated 29/111 (26.
13%) unique QIs, while pharma stakeholders generated 24/111 (21.
62%).
The total unique QIs across both stakeholder groups were 53/111 (47.
75%).
Two QIs were unanimously suggested and agreed upon by all stakeholder groups (7/7; 100%): 'Engages with patients and gains their buy-in' and 'Includes a core data set as part of outcomes'.
There was homogeneity in consensus on common QIs between Commercial – Market Access (P=0.
006), Market Access – Regulators (P=0.
006), Commercial – Prescribers (P=0.
001), Market Access – Prescribers (P=0.
033), and Commercial – Medical Affairs (P=0.
020).
Conclusions:There is sufficient evidence to support a multiple stakeholder approach for generating real-world evidence.
There was a mismatch between pharma and non-pharma stakeholders of 47.
75% indicating redundancies of QIs on each side of this divide.
Patients and Payor (non-pharma) groups have been highlighted for greater alignment with pharma stakeholder groups.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Woningcorporaties en Vastgoedontwikkeling
Woningcorporaties en Vastgoedontwikkeling
This summary highlights the findings of the PhD-thesis ‘Woningcorporaties en Vastgoedontwikkeling: Fit for Use’ (‘Housing associations and Real Estate Development: Fit for Use?’). ...
Ethics practices associated with reusing health data: An assessment of patient registries
Ethics practices associated with reusing health data: An assessment of patient registries
Abstract
Background
As routinely collected patient data have become increasingly accessible over the years, more and more atten...
Młodociani sprawcy przestępstw przeciwko mieniu
Młodociani sprawcy przestępstw przeciwko mieniu
The new Polish penal legislation of 1969 introduced special rules of criminal liability of young adult offenders' aged 17-20. In 1972 criminological research was undertaken in orde...
303 Mapping the Landscape of Surgical Registries in the United Kingdom
303 Mapping the Landscape of Surgical Registries in the United Kingdom
Abstract
Introduction
Well-designed surgical registries are essential for high-quality patient-centred evaluation of implantable...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Abstract
The rapid growth of open access publishing (OAP) has significantly improved the accessibility and dissemination of scientific knowledge. However, this expansion has also c...
Are Disaster and Emergency Plans Truly Complete?
Are Disaster and Emergency Plans Truly Complete?
The purpose of this paper is to provide guidance or template to libraries and also other different types of institutions as to how they can complete, update or write their disaster...

